Skip to main content
NCBI home page
Medicine logoLink to Medicine
. 2019 Oct 11;98(41):e17487. doi: 10.1097/MD.0000000000017487

Polymorphic variants conferring genetic risk to cervical lesions support GSTs as important associated loci

Sijuan Tian 1, Xiaofeng Yang 1, Li Zhang 1, Juan Zhao 1, Meili Pei 1, Yang Yu 1, Ting Yang 1,∗
Editor: Kimon Chatzistamatiou1
PMCID: PMC6799649  PMID: 31593112

Abstract

To analyze the association between glutathione S-transferases polymorphisms and the risk of cervical lesions.

Case-control studies focusing on the association between glutathione S-transferase polymorphisms and the risk of cervical lesions were collected from the PubMed, Web of Science, Cochrane Library, Embase, Medline, CNKI, VIP and Wanfang databases from inception to August 2018. Pooled odds ratios and 95% confidence intervals were employed to evaluate the strength of the association. Subgroup analysis and sensitivity analysis were used to test the potential discrepancy and robustness, respectively.

A total of 30 studies comprising 3961 patients and 4726 healthy controls satisfied the inclusion criteria. Of these, 6 studies contained information about GSTP1, 27 studies contained information about GSTM1, and 22 studies contained information about GSTT1. Our results supported that there was no statistical association between GSTP1 polymorphism and the risk of cervical lesions (odds ratio [OR] = 1.08, P = .40). The GSTM1 null variant showed increased susceptibility to cervical lesions (OR = 1.45, P < .001). Subgroup analysis revealed that the GSTM1 null variant caused cervical lesions among HPV infection cases (OR = 1.69, P = .02) and among the Chinese and Indian populations (OR = 2.24 and OR = 1.87, respectively, P < .001). The GSTT1 null variant increased the risk of cervical lesions in smokers (OR = 1.52, P = .03). The GSTT1 null genotype was also related to high-grade intraepithelial neoplasia (HSIL) and cervical cancer risk (OR = 1.30 and OR = 1.78, respectively, P < .05).

The GSTM1 null variant caused cervical lesions, especially among HPV infection cases and among the Chinese and Indian populations. The GSTT1 null variant increased the risk of cervical lesions in smokers and was also related to HISL and cervical cancer risk.

Keywords: cervical lesions, GSTM1, GSTP1, GSTT1, polymorphisms

1. Introduction

Cervical cancer ranks fourth for both incidence and mortality rates in women, with an estimated 570,000 cases and 311,000 deaths in 2018 worldwide. In lower human development index (HDI) regions, it is the second most frequently diagnosed cancer and the second leading cause of cancer death.[1] In China, the results indicated that an estimated 98,900 new cases and 30,500 cancer deaths occurred in 2015.[2] Human papillomavirus (HPV) is considered a major factor in cervical cancer. Other co-factors are also important in cervix carcinogenesis, including immune suppression, cigarette smoking, parity, and oral contraceptive use.

Glutathione S-transferases (GSTs) are a family of phase II enzymes that are responsible for the metabolism of various xenobiotics and carcinogens by catalyzing the conjugation of glutathione to electrophilic compounds.[3] Studies have shown that genetic variations in GSTs affect human phase II detoxification enzymes, thereby altering their ability to detoxify various exogenous and endogenous active species.[4]

Previous studies revealed that the GST genetic variants were related to the risk of several cancers, such as breast, lung, prostate, bladder, and nasopharyngeal cancer risk.[5] However, the results were controversial regarding whether GST polymorphisms would lead to the development of cervical lesions, so we conducted this meta-analysis about the relationship between GST genetic variants and cervical lesions risk.

2. Material and methods

2.1. Literature search strategy

We searched the Cochrane Library, Embase, Medline, PubMed, Web of Science, CNKI, Wanfang, and VIP databases by the following search terms: Glutathione Transferase[Mesh] or GST∗, glutathione S-transferase pi[Mesh] or GSTP1, glutathione S-transferase M1[Mesh] or GSTM1, glutathione S-transferase T1[Mesh] or GSTT1, polymorphism∗/variant∗/mutation∗/SNP, Uterine Cervical Neoplasm [Mesh]/cervix cancer/cervical cancer/cervical neoplasm∗/cervical carcinoma∗, and the combinations of these. In addition, we searched the reference lists of all identified articles manually to acquire more data.

2.2. Inclusion and exclusion criteria

Studies included needed to meet the following criteria: regarding on the association between GST gene polymorphisms (GSTP1/GSTM1/GSTT1) and the risk to cervical lesions; human study subjects; case-control studies; available and sufficient genotype distribution data to calculate odds ratios (ORs) and corresponding 95% confidence intervals (CIs); and diagnoses based on cervical biopsy pathology or cytology. Besides, if there were duplicate studies, the most complete one was reserved. Otherwise, the article was excluded if it did not satisfy the criteria above.

2.3. Data extraction and synthesis

Two investigators extracted relevant data from all the eligible studies independently. A third reviewer was invited to participate in the work when some disagreement occurred; consensus was ultimately reached by discussion. According to the 4th WHO Women's Genital Tumor Classification Guidelines, we defined cervical lesions as cervical cancer, high-grade intraepithelial neoplasia (HSIL), and low-grade intraepithelial neoplasia (LSIL). LSIL was equivalent to cervical intraepithelial neoplasia (CIN) grade 1, and HSIL included most amount of CIN2 and all CIN3 cases.[6] We gathered characteristics from all satisfied records: the first author, publication year, ethnicity, total numbers of cases and controls, source of controls, genotyping method.

2.4. Statistical analysis

Using the ORs and 95% CIs to assess the degree of association between GSTs polymorphic variants and cervix lesions. A Z-test revealed statistical significance when P < .05. I2 and Q statistic were applied to detect heterogeneity among different studies. There was no heterogeneity if I2 < 50% and P > .1 and a fixed effect model was used, otherwise we thought heterogeneity existed in the incorporated populations and a random effect model was used instead. Subsequently, we conducted a subgroup analysis according to HPV infection status, cigarette smoking, degree of cervix lesions, and ethnicity. Hardy-Weinberg equilibrium (HWE) was evaluated by chi-square test with P < .05 indicating a deviation from HWE. Sensitivity analysis was employed to estimate stability of the meta-analysis results by deleting all the studies one by one. Additionally, a Begg funnel plot and an Egger test were used to evaluate publication bias. The statistical analyses were performed using RevMan 5.3 (Cochrane Collaboration) and STATA 12.0 (StataCorp., College Station, TX, USA) software.

3. Results

3.1. Characteristics of included studies

By searching the electronic databases systematically, we initially retrieved 300 articles. After excluding duplicate studies, 207 articles remained. Further reviewing of the titles and abstracts of the identified studies allowed the removal of 169 articles. Of those removed, 141 were clearly irrelevant to GST polymorphisms, 20 were review papers or meta-analyses, 8 records were deleted for other reasons. We downloaded the remaining 38 articles as full-text reports and reviewed them carefully. Four records were excluded for containing duplicate samples, and the data were not available in other 4 studies. Finally, 30 case-control studies containing 3961 cases and 4726 controls were included, among which 6 studies were about GSTP1, 27 articles were on GSTM1, and 22 studies focused on GSTT1 (Fig. 1). The characteristics of included studies were presented at Table 1.

Figure 1.

Figure 1

Open in a new tab

Flow diagram of searching procedure.

Table 1.

Characteristics of the included studies.

3.1.

Open in a new tab

3.2. Meta-analysis results

There were 6 studies on the GSTP1 variant that included 897 cases and 1387 healthy controls. The meta-analysis results did not show a statistical association between GSTP1 polymorphism and the risk of cervical lesions in the dominant genetic model (OR = 1.08, P = .40) (Fig. 2).

Figure 2.

Figure 2

Open in a new tab

Forest plots of the association between GSTP1 polymorphism and susceptibility of cervical lesions in dominant genetic model.

A total of 27 case-control studies were included in the meta-analysis of GSTM1 involving 3383 cases and 3652 controls. The results showed that the GSTM1 null allele was related to an increased risk of cervical lesions (OR = 1.45, P < .001) (Fig. 3). Great heterogeneity existed in the GSTM1 studies (P < .001, I2 = 63%), thus, a random-effect model was employed. In addition, we conducted subgroup analysis based on HPV infection status, smoking status, degree of cervical lesions, ethnicity. The results presented in Table 2. The GSTM1 null variant was related to an increased risk of cervical lesions among HPV positive cases (OR = 1.69, P = .02) (Fig. 4), nonsmokers (OR = 1.73, P < .001), and Chinese and Indian populations (OR = 2.24 and OR = 1.87, respectively, P < .001), but was not related to the degree of cervical lesions (Table 2).

Figure 3.

Figure 3

Open in a new tab

Forest plots of the association between GSTM1 polymorphism and susceptibility of cervical lesions.

Table 2.

Meta-analysis results of GSTM1 polymorphism.

3.2.

Open in a new tab

Figure 4.

Figure 4

Open in a new tab

Subgroup analysis of the association between GSTM1 polymorphism and cervical lesions stratified by HPV infection status. HPV = human papillomavirus.

For the GSTT1 genotype, there were 2680 cases and 2971 controls incorporated in the study. The pooled OR suggested that the GSTT1 null genotype might not be related to cervical lesions (P = .06) (Fig. 5). Considering the heterogeneity, we performed a subgroup analysis stratified by HPV infection status, cigarette smoking, degree of cervical lesions, and ethnicity. The results revealed that the GSTT1 null variant increased cervical lesions in smokers (OR = 1.52, P = .03). In addition, the GSTT1 null variant was related to HISL and cervical cancer (OR = 1.30 and OR = 1.78, respectively, P < .05) but was not related to LSIL (Fig. 6). HPV infection status and ethnicity did not modify the association between GSTT1 polymorphism and cervical lesions (Table 3).

Figure 5.

Figure 5

Open in a new tab

Forest plots of the association between GSTT1 polymorphism and susceptibility of cervical lesions.

Figure 6.

Figure 6

Open in a new tab

Subgroup analysis of the association between GSTT1 polymorphism and cervical lesions stratified by degree of lesions.

Table 3.

Meta-analysis results of GSTT1 polymorphism.

3.2.

Open in a new tab

3.3. Detection for heterogeneity and sensitivity analysis

As presented in Tables 2 and 3, there was great heterogeneity among studies relating to GST genetic variants (I2 > 50%, P < .1). In consideration of this, we used a random effect model for the meta-analysis. Additionally, subgroup analysis stratified by HPV infection status, cigarette smoking, degree of cervical lesions, and ethnicity was performed to eliminate heterogeneity. Heterogeneity was clearly decreased in the ethnicity subgroup. This indicated that ethnicity might be a confounding factor and heterogeneity source, while the pooled ORs were substantially robust.

Sensitivity analysis was utilized to evaluate the stability of the meta-analysis by deleting all the studies one by one. The pooled ORs did not change significantly in any of the GST variants, indicating that the meta-analysis was robust and stable (Fig. 7).

Figure 7.

Figure 7

Open in a new tab

Sensitivity analysis of the association between GST SNPs and risk of cervical lesions. (A) GSTP1; (B) GSTM1; (C) GSTT1.

3.4. Publication bias

To detect publication bias, Begg funnel plot and Egger test were performed. The results indicated that no significant evidence of publication bias for GSTP1, GSTM1, and GSTT1 variant was observed in our study (P > .05) (Fig. 8).

Figure 8.

Figure 8

Open in a new tab

Publication bias of GST polymorphisms. (A, B). GSTP1, Begg test, P = .452, Egger test, P = .448; (C, D). GSTM1, Begg test, P = .144, Egger test, P = .122; (E, F). GSTT1, Begg test, P = .778, Egger test, P = .502.

4. Discussion

Cervical cancer is an outcome of virus-induced carcinogenesis. HPV is the primary etiology of cervical carcinogenesis but all HPV infections do not result in cervical cancer. Tobacco use, immune system function, use of oral contraceptive, number of sexual partners all modify the outcome of cervix lesions.

GSTs play an important role in protecting cells from oxidative damage and in modulating the induction of other enzymes and proteins in response to DNA damage, therefore, they are important for maintaining genomic integrity.[37] GSTs catalyzed the conjugation of glutathione to electrophilic substrates, which resulted in the enhanced renal clearance and reduced carcinogenic load from the cell.[38]

The GSTP1 G/A single nucleotide polymorphism caused valine (Val) took the place of isoleucine (Ile) at codon 105, resulting in decreased enzymatic activity and low ability to metabolize certain xenobiotics and carcinogens.[39] Biochemical studies indicated that the GSTP1 AA genotype was 2 to 3 times less stable[40] and might be associated with the risk of gynecological cancer. However, our results supported that GSTP1 AA genetic variant was not associated with the risk of cervix lesions, which was consistent with Zhao finding.[38] This might be attributed to an insufficient sample size.

With regard to the GSTM1 and GSTT1 genotypes, some studies indicated that the GSTM1 null or GSTT1 null variants contributed to cervical cancer susceptibility, while some studies showed that the 2 variants were not associated with cervical carcinogenesis. Our results supported that the GSTT1 null variant increased the risk of cervical lesions in smokers. The GSTT1 null genotype was also related to HISL and cervical cancer risk. The GSTM1 null variant increased susceptibility to cervical carcinogenesis. Subgroup analysis revealed that the GSTM1 null variant caused cervical lesions among HPV infection cases and among the Chinese and Indian populations. This implied that there were differences in ethnicity and environment. In addition, it elevated the risk of cervical lesions among women who were not smoking, which implied that the GSTM1 null genotype might be a risk factor independent of cigarette smoking.

A previous study demonstrated that the GST null genotype resulted in complete loss of the ability of the enzyme to bind genotoxic substrates. This leads to decreased detoxification ability, a reduction in the metabolic rate of intracellular toxic substances, and increased malignant transformation of cells, which thereby promoted tumorigenesis.[40] Several studies on the relationship between GST polymorphisms and cervical cancer risk were conducted. Compared with those studies, our meta-analysis included additional qualified studies to evaluate the association and therefore obtained more persuasive conclusions. Additionally, the study included the association of GSTP1, GSTM1, and GSTT1 genetic variants on cervical lesion risk, while previous studies were based on only one or two of the three variants. Moreover, to eliminate the effects of co-factors, we performed subgroup analysis stratified by HPV infection status, cigarette smoking, degree of cervical lesion and ethnicity. Thus, our findings provide stronger evidence for the association between GST genetic variants and cervical lesions.

There are some limitations to our study. First, the small sample size was insufficient to support our results regarding the GSTP1 genetic variant. Second, the incidence of cervical cancer is highest in sub-Saharan Africa, Latin America, the Caribbean, and Melanesia, where people of African origin account for the majority of the population.[1] However, there were no statistics and studies of interest focused on women of African descent. This caused bias in the relationship, which is concerning. Additionally, although we considered the effect of age on our conclusions and attempted to perform a subgroup analysis, inconsistent age grouping of the included studies prevented us from conducting a subgroup analysis stratified by age. Last but not least, GSTP1, GSTM1, and GSTT1 all belonged to the glutathione S-transferase family, playing an important role in protecting cells from oxidative damage and in metabolizing various carcinogens. As reported, the combination of the GSTM1 null, GSTT1 null, and GSTP1 AA genotypes was associated with an increased risk of gynecological cancer, while the GSTs alone were not.[23] Therefore, gene–gene interactions are likely more appropriate to assess disease risk than individual genes. In our meta-analysis, there was no association study between gene–gene interactions and the risk of cervical lesions. Future studies containing more comprehensive information are needed to obtain more reliable conclusions.

5. Conclusion

In general, the GSTP1 AA genotype was not associated with the risk of cervical lesions. The GSTM1 null variant caused cervix lesions, especially among HPV infection cases and among the Chinese and Indian populations. GSTT1 null variant increased the risk of cervical lesions in smokers and was also related to HISL and cervical cancer risk. Additional large, well-designed case-control studies are needed to authenticate these results.

Author contributions

Conceptualization: Sijuan Tian, Li Zhang, Ting Yang.

Data curation: Sijuan Tian, Xiaofeng Yang, Li Zhang, Juan Zhao, Meili Pei, Yang Yu, Ting Yang.

Formal analysis: Sijuan Tian, Xiaofeng Yang, Li Zhang, Juan Zhao, Yang Yu, Ting Yang.

Funding acquisition: Xiaofeng Yang, Juan Zhao, Ting Yang.

Investigation: Sijuan Tian, Xiaofeng Yang, Juan Zhao, Meili Pei, Yang Yu, Ting Yang.

Methodology: Sijuan Tian, Xiaofeng Yang, Juan Zhao, Meili Pei, Yang Yu, Ting Yang.

Project administration: Sijuan Tian, Xiaofeng Yang, Li Zhang, Ting Yang.

Resources: Ting Yang.

Software: Sijuan Tian, Ting Yang.

Supervision: Ting Yang.

Validation: Ting Yang.

Visualization: Sijuan Tian, Ting Yang.

Writing – original draft: Sijuan Tian, Ting Yang.

Writing – review & editing: Sijuan Tian, Ting Yang.

Footnotes

Abbreviations: CI = confidence interval, CIN = cervical intraepithelial neoplasia, GST = Glutathione S-transferase, HDI = human development index, HPV = human papillomavirus, HSIL = high-grade squamous intraepithelial neoplasia, LSIL = low-grade squamous intraepithelial neoplasia (LSIL), OR = odds ratio.

How to cite this article: Tian S, Yang X, Zhang L, Zhao J, Pei M, Yu Y, Yang T. Polymorphic variants conferring genetic risk to cervical lesions support GSTs as important associated loci. Medicine. 2019;98:41(e17487).

The research is supported by the Sci-ech Program Foundation of Shaanxi Province (2017SF-126).

Ethical approval: This article does not contain any studies with human participants or animals performed by any of the authors. Informed consent was not involved since all the data in this study were extracted from published articles.

The authors have no conflicts of interest to disclose.

References

  • [1].Bray F, Ferlay J, Soerjomataram I, et al. Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424. [DOI] [PubMed] [Google Scholar]
  • [2].Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016;66:115–32. [DOI] [PubMed] [Google Scholar]
  • [3].Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. Annu Rev Pharmacol Toxicol 2005;45:51–88. [DOI] [PubMed] [Google Scholar]
  • [4].Hengstler JG, Arand M, Herrero ME, et al. Polymorphisms of N-acetyltransferases, glutathione s-transferases, microsomal epoxide hydrolase and sulfotransferases: influence on cancer susceptibility. Recent Results Cancer Res 1998;154:47–85. [DOI] [PubMed] [Google Scholar]
  • [5].Liu Y, Xu LZ. Meta-analysis of association between GSTM1 gene polymorphism and cervical cancer. Asian Pac J Trop Med 2012;5:480–4. [DOI] [PubMed] [Google Scholar]
  • [6].Kuraman RJ, Carcangiu ML, Herrington CS, et al. WHO Classification of Tumours of Female Reproductive Organs. 4th ed.Lyon: IARC; 2014. [Google Scholar]
  • [7].Agorastos T, Papadopoulos N, Lambropoulos AF, et al. Glutathione-S-transferase M1 and T1 and cytochrome P1A1 genetic polymorphisms and susceptibility to cervical intraepithelial neoplasia in Greek women. Eur J Cancer Prev 2007;16:498–504. [DOI] [PubMed] [Google Scholar]
  • [8].Chagas BS, Apad G, Paiva SSL, J, et al. Synergic effect of oral contraceptives, GSTP1 polymorphisms, and high-risk HPV infection in development of cervical lesions. Genet Mol Res 2017;16: doi: 10.4238/gmr16039742. [DOI] [PubMed] [Google Scholar]
  • [9].Chen C, Madeleine MM, Weiss NS, et al. Glutathione S-transferase M1 genotypes and the risk of squamous carcinoma of the cervix: a population-based case-control study. Am J Epidemiol 1999;150:568–72. [DOI] [PubMed] [Google Scholar]
  • [10].Cseh J, Pázsit E, Orsós Z, et al. Effect of glutathione-S-transferase M1 and T1 allelic polymorphisms on HPV-induced cervical precancer formation. Anticancer Res 2011;31:3051–5. [PubMed] [Google Scholar]
  • [11].de Carvalho CR, da Silva ID, Pereira JS, et al. Polymorphisms of p53, GSTM1 and GSTT1, and HPV in uterine cervix adenocarcinoma. Eur J Gynaecol Oncol 2008;29:590–3. [PubMed] [Google Scholar]
  • [12].Goodman MT, Mcduffie K, Hernandez B, et al. CYP1A1, GSTM1, and GSTT1 polymorphisms and the risk of cervical squamous intraepithelial lesions in a multiethnic population. Gynecol Oncol 2001;81:263–9. [DOI] [PubMed] [Google Scholar]
  • [13].Hasan S, Hameed A, Saleem S, et al. The association of GSTM1 and GSTT1 polymorphisms with squamous cell carcinoma of cervix in Pakistan. Tumour Biol 2015;36:5195–9. [DOI] [PubMed] [Google Scholar]
  • [14].Jee SH, Lee JE, Kim S, et al. GSTP1 polymorphism, cigarette smoking and cervical cancer risk in korean women. Yonsei Med J 2002;43:712–6. [DOI] [PubMed] [Google Scholar]
  • [15].Kim JW, Lee CG, Park YG, et al. Combined analysis of germline polymorphisms of p53, GSTM1, GSTT1, CYP1A1, and CYP2E1 - Relation to the incidence rate of cervical carcinoma. Cancer 2000;88:2082–91. [DOI] [PubMed] [Google Scholar]
  • [16].Kiran B, Karkucak M, Ozan H, et al. GST (GSTM1, GSTT1, and GSTP1) polymorphisms in the genetic susceptibility of Turkish patients to cervical cancer. J Gynecol Oncol 2010;21:169–73. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [17].Lee SA, Kim JW, Roh JW, et al. Genetic polymorphisms of GSTM1, p21, p53 and HPV infection with cervical cancer in Korean women. Gynecol Oncol 2004;93:14–8. [DOI] [PubMed] [Google Scholar]
  • [18].Ma CL, Liu Y, Lu XM, et al. The relationship between the incidence of cervical cancer and GSTM1 gene in Uygur women. Chin J Obstet Gynecol 2009;44:629–31. [Google Scholar]
  • [19].Natphopsuk S, Settheethamishida W, Settheetham D, et al. Lack of participation of the GSTM1 polymorphism in cervical cancer development in northeast Thailand. Asian Pac J Cancer Prev 2015;16:1935–7. [DOI] [PubMed] [Google Scholar]
  • [20].Nishino K, Sekine M, Kodama S, et al. Cigarette smoking andglutathione S-transferase M1 polymorphism associated with risk for uterine cervical cancer. J Obstet Gynaecol Res 2008;34:994–1001. [DOI] [PubMed] [Google Scholar]
  • [21].Niwa Y, Hirose K, Nakanishi T, et al. Association of the NAD(P)H: quinone oxidoreductase C609T polymorphism and the risk of cervical cancer in Japanese subjects. Gynecol Oncol 2005;96:423–9. [DOI] [PubMed] [Google Scholar]
  • [22].Nunobiki O, Ueda M, Akise H, et al. GSTM1, GSTT1, and NQO1 polymorphisms in cervical carcinogenesis. Human Cell 2015;28:109–13. [DOI] [PubMed] [Google Scholar]
  • [23].Palma S, Novelli F, Padua L, et al. Interaction between glutathione-S-transferase polymorphisms, smoking habit, and HPV infection in cervical cancer risk. J Cancer Res Clin Oncol 2010;136:1101–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [24].Satinder K, Sobti RC, Pushpinder K. Impact of single nucleotide polymorphism in chemical metabolizing genes and exposure to wood smoke on risk of cervical cancer in North-Indian women. Exp Oncol 2017;39:69–74. [PubMed] [Google Scholar]
  • [25].Settheetham-Ishida W, Yuenyao P, Kularbkaew C, et al. Glutathione S-transferase (GSTM1 and GSTT1) polymorphisms in cervical cancer in Northeastern Thailand. Asian Pac J Cancer Prev 2009;10:365–8. [PubMed] [Google Scholar]
  • [26].Sharma A, Gupta S, Sodhani P, et al. Glutathione S-transferase M1 and T1 polymorphisms, cigarette smoking and HPV infection in precancerous and cancerous lesions of the uterine cervix. Asian Pac J Cancer Prev 2015;16:6429–38. [DOI] [PubMed] [Google Scholar]
  • [27].Sharma A, Sharma JK, Murthy NS, et al. Polymorphisms at GSTM1 and GSTT1 gene loci and susceptibility to cervical cancer in Indian population. Neoplasma 2004;51:12–6. [PubMed] [Google Scholar]
  • [28].Sierra-Torres CH, Au WW, Arrastia CD, et al. Polymorphisms for chemical metabolizing genes and risk for cervical neoplasia. Environ Mol Mutagen 2003;41:69–76. [DOI] [PubMed] [Google Scholar]
  • [29].Sierra-Torres CH, Arboleda-Moreno YY, Orejuela-Aristizabal L. Exposure to wood smoke, HPV infection, and genetic susceptibility for cervical neoplasia among women in Colombia. Environ Mol Mutagen 2006;47:553–61. [DOI] [PubMed] [Google Scholar]
  • [30].Singh H, Sachan R, Devi S, et al. Association of GSTM1, GSTT1, and GSTM3 gene polymorphisms and susceptibility to cervical cancer in a North Indian population. Am J Obstet Gynecol 2008;198:303.e1–6. [DOI] [PubMed] [Google Scholar]
  • [31].Sobti RC, Kaur S, Kaur P, et al. Interaction of passive smoking with GST (GSTM1, GSTT1, and GSTP1) genotypes in the risk of cervical cancer in India. Cancer Genet Cytogenet 2006;166:117–23. [DOI] [PubMed] [Google Scholar]
  • [32].Song GY, Shao SL, Song ZY. Association of single nucleotide polym orphism in glutathione S-transferase with susceptibility to cervical cancer. Tumour J World 2006;5:192–4. [Google Scholar]
  • [33].Stosic I, Grujicic D, Arsenijevic S, et al. Glutathione S-transferase T1 and M1 polymorphisms and risk of uterine cervical lesions in women from central Serbia. Asian Pac J Cancer Prev 2014;15:3201–5. [DOI] [PubMed] [Google Scholar]
  • [34].Ueda M, Toji E, Nunobiki O, et al. Germline polymorphisms of glutathione-S-transferase GSTM1, GSTT1 and p53 codon 72 in cervical carcinogenesis. Human Cell 2010;23:119–25. [DOI] [PubMed] [Google Scholar]
  • [35].Wang J, Wang T, Song J, et al. The relationship between glutathione S-transferase M1 polymorphism, HPV16 infection and cervical cancer. Chin J Gerontol 2018;38:1606–8. [Google Scholar]
  • [36].Zhou Q, Wang JT, Shao SL, et al. The study of the relationship between glutathione S-transferase M1, T1 genotypes and the risk of cervical cancer. Mod Prev Med 2006;33:269–71. [Google Scholar]
  • [37].Sengupta D, Guha U, Mitra S, et al. Meta-analysis of polymorphic variants conferring genetic risk to cervical cancer in Indian women supports CYP1A1 as an important associated locus. Asian Pac J Cancer Prev 2018;19:2071–81. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [38].Zhao E, Hu K, Zhao Y. Associations of the glutathione S-transferase P1 Ile105Val genetic polymorphism with gynecological cancer susceptibility: a meta-analysis. Oncotarget 2017;8:41734–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [39].Johansson AS, Stenberg G, Widersten M, et al. Structure-activity relationships and thermal stability of human glutathione transferase P1-1 governed by the H-site residue 105. J Mol Biol 1998;278:687–98. [DOI] [PubMed] [Google Scholar]
  • [40].Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995;30:445–600. [DOI] [PubMed] [Google Scholar]

Articles from Medicine are provided here courtesy of Wolters Kluwer Health

RESOURCES